Literature DB >> 19962028

Acute rheumatic fever and rheumatic heart disease in indigenous populations.

Andrew C Steer1, Jonathan R Carapetis.   

Abstract

Acute rheumatic fever and rheumatic heart disease are diseases of socioeconomic disadvantage. These diseases are common in developing countries and in Indigenous populations in industrialized countries. Clinicians who work with Indigenous populations need to maintain a high index of suspicion for the potential diagnosis of acute rheumatic fever, particularly in patients presenting with joint pain. Inexpensive medicines, such as aspirin, are the mainstay of symptomatic treatment of rheumatic fever; however, antiinflammatory treatment has no effect on the long-term rate of progression or severity of chronic valvular disease. The current focus of global efforts at prevention of rheumatic heart disease is on secondary prevention (regular administration of penicillin to prevent recurrent rheumatic fever), although primary prevention (timely treatment of streptococcal pharyngitis to prevent rheumatic fever) is also important in populations in which it is feasible.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19962028     DOI: 10.1016/j.pcl.2009.09.011

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  9 in total

1.  Echocardiographic screening for rheumatic heart disease-some answers, but questions remain.

Authors:  Marc G W Rémond; Graeme P Maguire
Journal:  Transl Pediatr       Date:  2015-07

2.  Adherence to secondary prophylaxis and disease recurrence in 536 Brazilian children with rheumatic fever.

Authors:  Christina F Pelajo; Jorge M Lopez-Benitez; Juliana M Torres; Sheila Kf de Oliveira
Journal:  Pediatr Rheumatol Online J       Date:  2010-07-26       Impact factor: 3.054

3.  Prediction of residual valvular lesions in rheumatic heart disease: role of adhesion molecules.

Authors:  Mona Hafez; Sohier Yahia; Waleed Eldars; Heba Eldegla; Mohamed Matter; Gehan Attia; Samia Hawas
Journal:  Pediatr Cardiol       Date:  2012-09-18       Impact factor: 1.655

4.  Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship.

Authors:  Mehfuz Zaman; Abu-Baker M Abdel-Aal; Yoshio Fujita; Karen S M Phillipps; Michael R Batzloff; Michael F Good; Istvan Toth
Journal:  PLoS One       Date:  2012-01-12       Impact factor: 3.240

Review 5.  Group A Streptococcus, Acute Rheumatic Fever and Rheumatic Heart Disease: Epidemiology and Clinical Considerations.

Authors:  Liesl J Zühlke; Andrea Beaton; Mark E Engel; Christopher T Hugo-Hamman; Ganesan Karthikeyan; Judith M Katzenellenbogen; Ntobeko Ntusi; Anna P Ralph; Anita Saxena; Pierre R Smeesters; David Watkins; Peter Zilla; Jonathan Carapetis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-02

Review 6.  Health Challenges of the Pacific Region: Insights From History, Geography, Social Determinants, Genetics, and the Microbiome.

Authors:  Paul F Horwood; Arnaud Tarantola; Cyrille Goarant; Mariko Matsui; Elise Klement; Masahiro Umezaki; Severine Navarro; Andrew R Greenhill
Journal:  Front Immunol       Date:  2019-09-13       Impact factor: 7.561

7.  Rheumatic heart disease in The Gambia: clinical and valvular aspects at presentation and evolution under penicillin prophylaxis.

Authors:  Lamin E S Jaiteh; Lamin Drammeh; Suzanne T Anderson; John Mendy; Samba Ceesay; Umberto D'Alessandro; Jonathan Carapetis; Mariana Mirabel; Annette Erhart
Journal:  BMC Cardiovasc Disord       Date:  2021-10-18       Impact factor: 2.298

Review 8.  Atrial fibrillation in the Indigenous populations of Australia, Canada, New Zealand, and the United States: a systematic scoping review.

Authors:  Judith M Katzenellenbogen; John A Woods; Tiew-Hwa Katherine Teng; Sandra C Thompson
Journal:  BMC Cardiovasc Disord       Date:  2015-08-13       Impact factor: 2.298

9.  Benzathine penicillin adherence for secondary prophylaxis among patients affected with rheumatic heart disease attending Mulago Hospital.

Authors:  Charles Musoke; Charles Kiiza Mondo; Emmy Okello; Wanzhu Zhang; Barbara Kakande; Wilson Nyakoojo; Juergen Freers
Journal:  Cardiovasc J Afr       Date:  2013-05       Impact factor: 1.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.